Journal for ImmunoTherapy of Cancer Best Paper Awards

The Journal for ImmunoTherapy of Cancer (JITC) Best Paper Awards celebrate excellence in scientific research and are awarded to researchers demonstrating leadership in the field as well as innovation and high-quality execution and discussion in their manuscripts. Papers published in the last 12 months authored by Society for Immunotherapy of Cancer (SITC) members were eligible for nomination for this award.

Articles nominated in this category present innovative research in basic medical sciences that have a direct relevance to future research in clinical medicine.

Genevieve M. Weir, PhD

ImmunoVaccine

“Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide”

Genevieve M. Weir, Olga Hrytsenko, Tara Quinton, Neil L. Berinstein, Marianne M. Stanford and Marc Mansour

Journal for ImmunoTherapy of Cancer 2016, 4:68 (18 October 2016)

Papers in this category present clinical research that has a clear potential to optimize patient care, with particular emphasis on high quality randomized controlled trials, novel combination treatments, therapies, novel diagnostic or prognostic insights and new insights into mechanism of action.

Kristen M. Hege, MD

Celgene

“Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer”

Kristen M. Hege, Emily K. Bergsland, George A. Fisher, John J. Nemunaitis, Robert S. Warren, James G. McArthur, Andy A. Lin, Jeffrey Schlom, Carl H. June and Stephen A. Sherwin

Journal for ImmunoTherapy of Cancer 2017, 5:22 (21 March 2017)